Protocol Ledger

NCT06058585 · Phase III · RECRUITING

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Interventional Phase III clinical trial protocol NCT06058585 sponsored by The George Institute in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-04 Enrollment: 2,000 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06058585
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2,000 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06058585
Protocol FieldVerified Registry Value
NCT IdentifierNCT06058585
Consolidated Lead SponsorThe George Institute
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment2,000 participants (ESTIMATED)
Registered Start Date2024-09-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06058585
Hospital Research SiteLocationSite Profile
Westmead HospitalWestmead, AustraliaOpen Hospital Dossier ->
Austin HealthHeidelberg, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI